Mitochondrial augmentation therapy of muscle diseases

A method for treating a muscle disease or a muscle disorder or a symptom thereof in a patient in need thereof, comprising:

• of administering parenterally a therapeutically effective amount of a pharmaceutical composition to the patient, the pharmaceutical composition comprising at least 5×105 to 5×109 human stem cells, wherein the human stem cells are enriched with human exogenous mitochondria, relative to untreated human stem cells, and wherein the pharmaceutical composition further comprises non-enriched stem cells, megakaryocytes, erythrocytes, mast cells, myeloblasts, basophils, neutrophils, eosinophils, monocytes, macrophages, natural killer (NK) cells, small lymphocytes, T lymphocytes, B lymphocytes, plasma cells, reticular cells, or a combination thereof;
• wherein the muscle disease or disorder is not a mitochondrial disease or disorder caused by a pathogenic mutation in mitochondrial DNA or by a pathogenic mutation in nuclear DNA encoding a mitochondrial protein.